RLRenee R. Li

Renee R. Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Renee R. Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher John Charles

    Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch 8014, New Zealand

    3 shared publications
  • A. Mark Richards

    Cardiovascular Research Institute National University Heart Centre Singapore

    1 shared publication
  • Andy Tay

    Department of Biomedical Engineering, National University of Singapore, Singapore, Singapore

    1 shared publication
  • Asim Shabbir

    National University Cancer Institute, Singapore, National University Health System, Singapore; University Surgical Cluster, National University Health System, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore

    1 shared publication
  • Boon Cher Goh

    Cancer Science Institute of Singapore, National University of Singapore, Singapore

    1 shared publication
  • Carolyn S.P. Lam

    Cardiovascular Research Institute National University Heart Centre Singapore

    1 shared publication

Latest Publications

  • Sponge‐Like Microneedles Spatially Sequester Chemokines and Deplete Monocytes to Alleviate Inflammatory Skin Disorders

    by Zhicheng Le, Yufeng Shou, Renee R. Li, Ling Liu, Runcheng Tan, Christopher John Charles, Zhijia Liu, Yongming Chen, Andy Tay

    Persistent inflammation, characterized by the intense interplay of inflammatory chemokine secretion and immune cell infiltration, is a hallmark of many skin disorders including diabetic wounds and psoriasis with inadequate therapeutic interventions. Monocyte chemotactic protein‐1 (MCP‐1) is an inflammatory chemokine that plays a key role in recruiting and polarizing monocytes into pro‐inflammatory macrophages to establish a vicious cycle that worsens the inflamed tissue microenvironment. Here, the sponge‐like microneedles (HPMN) technology is described to alleviate inflammatory skin disorders. Heparin/4‐arm PEG‐NH2 network crosslinked onto microneedle surface spatially attracted and sequestered multiple inflammatory chemokines including MCP‐1. Enrichment of MCP‐1 on microneedles recruits and traps inflammatory monocytes within the porous structure of microneedles. Subsequent removal of microneedles not only depletes inflammatory chemokine, MCP‐1, but also its cellular source. As a result, HPMN treatment facilitates 47.1% smaller open wound area in mice and 27.2% shorter wound length in pigs. To demonstrate the versatility of the HPMN technology, it is also shown that combining the method with standard‐of‐care immunosuppressants reduces 45.1% epidermis thickening and attenuated immune cell influx in a mouse psoriasis model. Overall, the HPMN technology is a novel demonstration of employing inflammatory chemokine and cell extraction to treat a broad range of inflammatory skin disorders.


  • Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model

    by Hon Lyn Tan, Guowei Kim, Christopher John Charles, Renee R. Li, Clarisse Jm. Jang, Asim Shabbir, Koy Min Chue, Chia Hui Tai, Raghav Sundar, Boon Cher Goh, et al.


  • Open Access

    A Porcine Model of Heart Failure with Preserved Ejection Fraction: Magnetic Resonance Imaging and Metabolic Energetics

    by Christopher J. Charles, Philip Lee, Renee R. Li, Teresa Yeung, Stephane M. Ibraham Mazlan, Zhi Wei Tay, Desiree Abdurrachim, Xing Qi Teo, Wei-Hsin Wang, Dominique P.V. de Kleijn, et al.

    Aims A significant proportion of heart failure (HF) patients have HF preserved ejection fraction (HFpEF). The lack of effective treatments for HFpEF remains a critical unmet need. A key obstacle to therapeutic innovation in HFpEF is the paucity of pre‐clinical models. Although several large animal models have been reported, few demonstrate progression to decompensated HF. We have established a model of HFpEF by enhancing a porcine model of progressive left ventricular (LV) pressure overload and characterized HF in this model including advanced cardiometabolic imaging using cardiac magnetic resonance imaging and hyperpolarized carbon‐13 magnetic resonance spectroscopy. Methods and results Pigs underwent progressive LV pressure overload by means of an inflatable aortic cuff. Pigs developed LV hypertrophy (50% increase in wall thickness, P < 0.001, and two‐fold increase in mass compared to sham control, P < 0.001) with no evidence of LV dilatation but a significant increase in left atrial volume (P = 0.013). Cardiac magnetic resonance imaging demonstrated T1 modified Look‐Locker inversion recovery values increased in 16/17 segments compared to sham pigs (P < 0.05–P < 0.001) indicating global ventricular fibrosis. Mean LV end‐diastolic (P = 0.047) and pulmonary capillary wedge pressures (P = 0.008) were elevated compared with sham control. One‐third of the pigs demonstrated clinical signs of frank decompensated HF, and mean plasma BNP concentrations were raised compared with sham control (P = 0.008). Cardiometabolic imaging with hyperpolarized carbon‐13 magnetic resonance spectroscopy agreed with known metabolic changes in the failing heart with a switch from fatty acid towards glucose substrate utilization. Conclusions Progressive aortic constriction in growing pigs induces significant LV hypertrophy with cardiac fibrosis associated with left atrial dilation, raised filling pressures, and an ability to transition to overt HF with raised BNP without reduction in LVEF. This model replicates many aspects of clinical HFpEF with a predominant background of hypertension and can be used to advance understanding of underlying pathology and for necessary pre‐clinical testing of novel candidate therapies.